Instituto de Olhos de Goiania
27
0
0
23
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 27 trials
100.0%
+13.5% vs industry average
52%
14 trials in Phase 3/4
0%
0 of 23 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
Analysis of the Microbiota in Goldmann Applanation Tonometers at a Reference Service in Goiânia
Role: lead
Epidemiology of Conjunctivitis in the Emergency Department
Role: lead
Evaluation of Adherence to Clinical Treatment of Glaucoma
Role: lead
Assessment of Color Vision in Diabetic Patients
Role: lead
Comparative Study Between Tonometers
Role: lead
Capsulotomy YAG Laser
Role: lead
TPS After Upper Blepharoplasty
Role: lead
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
Role: lead
Increased Prevalence of Myopia in a Ophthalmologic Hospital in Goiânia - Goiás
Role: lead
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Role: lead
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
Role: lead
Ranibizumab for Myopic Neovascularization
Role: lead
Intrastromal Corneal Ring for Ectasia After Refractive Surgery (Anel)
Role: lead
Different Surgical Techniques for Pterygium Surgery
Role: lead
Subconjunctival Bevacizumab and Recurrent Pterygium
Role: lead
Epidemiological Profile of Ophthalmological Care in the Public Service in Brazil
Role: lead
Corneal Sensitivity Cross-linking Keratoconus
Role: lead
Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
Role: lead
The Effect of Bevacizumab on Corneal Neovascularization
Role: lead
Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
Role: lead